These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29273130)

  • 1. Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis.
    Bożek A; Kołodziejczyk K; Jarząb J
    Ann Allergy Asthma Immunol; 2018 Jan; 120(1):53-58. PubMed ID: 29273130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
    Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C
    J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different Development Forms of Local Allergic Rhinitis towards Birch.
    Bozek A; Winterstein J; Galuszka B; Jarzab J
    Biomed Res Int; 2020; 2020():3408561. PubMed ID: 32596297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects.
    Ceuppens JL; Bullens D; Kleinjans H; van der Werf J;
    Clin Exp Allergy; 2009 Dec; 39(12):1903-9. PubMed ID: 20085600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BASALIT trial: double-blind placebo-controlled allergen immunotherapy with rBet v 1-FV in birch-related soya allergy.
    Treudler R; Franke A; Schmiedeknecht A; Ballmer-Weber B; Worm M; Werfel T; Jappe U; Biedermann T; Schmitt J; Brehler R; Kleinheinz A; Kleine-Tebbe J; Brüning H; Ruëff F; Ring J; Saloga J; Schäkel K; Holzhauser T; Vieths S; Simon JC
    Allergy; 2017 Aug; 72(8):1243-1253. PubMed ID: 27998002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of D. pteronyssinus immunotherapy in local allergic rhinitis: a double-blind placebo-controlled clinical trial.
    Rondón C; Campo P; Salas M; Aranda A; Molina A; González M; Galindo L; Mayorga C; Torres MJ; Blanca M
    Allergy; 2016 Jul; 71(7):1057-61. PubMed ID: 27008542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of birch pollen allergoid subcutaneous immunotherapy: A 2-year double-blind, placebo-controlled, randomized trial plus 1-year open-label extension.
    Worm M; Rak S; Samoliński B; Antila J; Höiby AS; Kruse B; Lipiec A; Rudert M; Valovirta E
    Clin Exp Allergy; 2019 Apr; 49(4):516-525. PubMed ID: 30570787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Differences between Local and Systemic Allergic Rhinitis Induced by Birch Pollen.
    Bozek A; Zalejska Fiolka J; Krajewska Wojtys A; Galuszka B; Cudak A
    Int Arch Allergy Immunol; 2020; 181(11):831-838. PubMed ID: 32772017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allergen immunotherapy for birch pollen-allergic patients: recent advances.
    Moingeon P; Floch VB; Airouche S; Baron-Bodo V; Nony E; Mascarell L
    Immunotherapy; 2016 May; 8(5):555-67. PubMed ID: 27140409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.
    Möbs C; Ipsen H; Mayer L; Slotosch C; Petersen A; Würtzen PA; Hertl M; Pfützner W
    J Allergy Clin Immunol; 2012 Nov; 130(5):1108-1116.e6. PubMed ID: 23021882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen.
    Subbarayal B; Schiller D; Möbs C; de Jong NW; Ebner C; Reider N; Bartel D; Lidholm J; Pfützner W; Gerth van Wijk R; Vieths S; Bohle B
    Allergy; 2013 Nov; 68(11):1377-86. PubMed ID: 24053565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
    Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
    Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study.
    Höiby AS; Strand V; Robinson DS; Sager A; Rak S
    Clin Exp Allergy; 2010 Jul; 40(7):1062-70. PubMed ID: 20642579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT-birch pollen extract for the treatment of allergic rhinitis: results of a phase II study.
    Pfaar O; van Twuijver E; Boot JD; Opstelten DJ; Klimek L; van Ree R; Diamant Z; Kuna P; Panzner P
    Allergy; 2016 Jan; 71(1):99-107. PubMed ID: 26417901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salivary Immunoglobulin A, E, and G4 Levels Specific to Dermatophagoides pteronyssinus in Allergic Rhinitis Patients Treated With Subcutaneous Immunotherapy.
    Liu Y; Xing Z; Wang J; Geng C
    Am J Rhinol Allergy; 2018 Nov; 32(6):458-464. PubMed ID: 30124065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma.
    Wahn U; Bachert C; Heinrich J; Richter H; Zielen S
    Allergy; 2019 Mar; 74(3):594-604. PubMed ID: 30183091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation.
    Buczyłko K; van der Werf JF; Boot D; van Ree R
    Int Arch Allergy Immunol; 2017; 172(3):183-186. PubMed ID: 28380494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
    Hylander T; Latif L; Petersson-Westin U; Cardell LO
    J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic alterations and efficacy of subcutaneous immunotherapy with Dermatophagoides pteronyssinus in monosensitized and polysensitized patients.
    Soyyigit S; Guloglu D; Ikinciogullari A; Secil D; Oztuna D; Mungan D; Misirligil Z; Sin BA
    Ann Allergy Asthma Immunol; 2016 Mar; 116(3):244-251.e2. PubMed ID: 26945497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
    Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
    Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.